THERAPEUTIC USES OF L-4-CHLOROKYNURENINE

• US 20190321317A1
• Filed: 05/06/2019
• Published: 10/24/2019
• Est. Priority Date: 05/22/2015
• Status: Abandoned Application

• Current Assignee: VistaGen Therapeutics, Inc.
• Original Assignee: VistaGen Therapeutics, Inc.
• Inventors: SNODGRASS, H. Ralph
• Application Number:
  US16/403,974
• Publication Number:
  US 20190321317A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Pharmaceutical compositions comprising L-4-chlorokynurenine and associated therapeutic methods are provided for the treatment of certain neurological and other conditions.

Claims

1-6. -6. (canceled)

7. A method of treating tinnitus by administering an effective dose of L-4-chlorokynurenine.

8. The method of claim 7, wherein the effective dose of L-4-chlorokynurenine is administered ranges from about 50 mg to about 1,800 mg per day or is an amount of 360, 1,080 or 1,440 mg per day;

and wherein the L-4-chlorokynurenine is optionally administered together with a pharmaceutically acceptable carrier or excipient.

10. The method of claim 7, wherein the L-4-chlorokynurenine is administered together with a pharmaceutically acceptable carrier or excipient as a daily unit dose ranging from about 50 mg to about 1,800 mg per day.

11. The method of claim 7, wherein the L-4-chlorokynurenine is administered together with a pharmaceutically acceptable carrier or excipient as a daily unit dose of 360, 1,080 or 1,440 mg.

12. The method of claim 7, wherein the effective dose of L-4-chlorokynurenine administered produces plasma levels of 7-chlorokynurenic acid ranging from about 15 ng/ml to about 65 ng/ml, ranging from about 65 ng/ml to about 300 ng/ml or ranging from about 300 ng/ml to about 550 ng/ml.

13. The method of claim 12, wherein the L-4-chlorokynurenine is administered together with a pharmaceutically acceptable carrier or excipient.

9. A pharmaceutical composition comprising a therapeutically acceptable amount of L-4-chlorokynurenine packaged with a label indicating the use of the composition for the treatment of tinnitus.